The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
The role of HER-2/neu, p53, Bcl-2 and Ki-67 in patients with lung cancer Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency Year: 2019
Prognostic significance and correlation between Akt phosphorylation and loss of PTEN protein expression in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005
The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005
MDM2 gene amplification and mdm2 protein expression in NSCLC cells Source: Eur Respir J 2005; 26: Suppl. 49, 91s Year: 2005
E-cadherin and beta-catenin expression in imprints of NSCLC. Relationship with prognostic parameters Source: Eur Respir J 2006; 28: Suppl. 50, 769s Year: 2006
Immunohistocemical expression of P53 and BCL-2 in pateints with lung cancer: correlation with survival time Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
Expression of survivin and p53 protein in pulmonary tumours Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Immunohistochemical expression of Bcl-2 and p53 in patients with lung cancer: Correlation with survival time Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Correlation between expression of p53, pRb, mdm2, p21WAF1/CIP1, PCNA, cyclin D1 and apoptotic index (AI) in non-small cell lung cancer (NSCLC) cells Source: Annual Congress 2006 - Molecular pathology and genetics of lung cancer Year: 2006
Apoptosis regulatory protein (p53, Bcl-2, survivin) expression in lung cancer-preliminary study Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008
BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer Source: Eur Respir J 2002; 19: 134-140 Year: 2002
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Clinical significance of serum survivin, MGB-1 and Pref-1 levels during chemotherapy of lung cancer Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Correlation of p53, EGFR and HER2 expression in the diagnostic biopsies and the corresponding resected tumours in NSCLC Source: Eur Respir J 2003; 22: Suppl. 45, 198s Year: 2003
Combined expression of p53, Bcl-2 and p21WAF-1 proteins in endobronchial biopsies may be associated with lung cancer prognosis Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001
c-erbB-1 and c-erbB-2 receptors genetic abnormalities and protein expression in lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004
Relationship between a clinical drug resistance and immunohistochemical expression of P-glycoprotien, multidrug resistance protein, and p53 in small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002
Distribution of BCL-2 gene expression and its prognostic value in non-small cell pulmonary cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002